摘要
目的观察玻璃体腔注射康柏西普联合黄斑格栅光凝治疗视网膜中央静脉阻塞(CRVO)继发黄斑水肿(ME)的疗效。方法选择2018年6月~2019年6月于我院治疗的43例(43眼)CRVO继发ME患者,按治疗方式的不同分为联合治疗组(22例,22眼)和单纯注射组(21例,21眼),所有患者均先行康柏西普玻璃体腔注射,每月1次,连续3个月。联合治疗组在第3次注射后1周,予患眼黄斑格栅光凝治疗,单纯注射组不处理,每月复查。当患者最佳矫正视力(BCVA)下降2行及以上或黄斑中心视网膜厚度(CMT)增加≥100μm,认为ME复发,予再治疗,联合治疗组给予康柏西普玻璃体腔注射联合黄斑格栅光凝治疗,单纯注射组给予康柏西普玻璃体腔注射。观察2组患者治疗后1个月、3个月、6个月BCVA、CMT的变化。结果经过初始3针康柏西普治疗后,2组患者的BCVA均较注射前提高,CMT较注射前减少,差异有统计学意义(P<0.05)。单纯注射组患者在治疗后1个月、3个月、6个月的BCVA均高于联合治疗组,但差异无统计学意义(P>0.05)。单纯注射组治疗后1个月CMT稍低于联合治疗组,差异无统计学意义(P>0.05),单纯注射组治疗后3个月、6个月CMT低于联合治疗组,差异有统计学意义(P<0.05)。观察期间联合治疗组玻璃体注药7次,单纯注射组玻璃体腔注药37次。结论连续玻璃体腔注射康柏西普可以快速提高CRVO患者的BCVA,减轻ME,联合黄斑格栅光凝治疗可以有效控制ME的复发,减少玻璃体腔注药的次数,减轻患者的经济负担。
Objective To observe the effect of intravitreal injection of conbercept combined with macular grid photocoagulation for macular edema(ME)secondary to central retinal vein occlusion(CRVO).Methods Forty-three patients(43 eyes)with ME secondary to CRVO,who were treated in our hospital from June 2018 to June 2019,were divided into combination therapy group(22 cases,22eyes)and conbercept monotherapy group(21 cases,21eyes)according to the different treatment methods.All patients initially received 3 monthly conbercept injections.The combination therapy group was treated with macular grid photocoagulation one week after the 3rd injection of conbercept,and the conbercept monotherapy group was not treated.The patients were re-examined every month.When the best corrected visual acuity(BCVA)decreased by 2 lines or central macular thickness(CMT)increased≥100μm,ME recurred and needed retreatment.The conbercept monotherapy group was treated with intravitreal conbercept injection combined with macular grid photocoagulation,the conbercept monotherapy group was treated with intravitreal conbercept injection.The changes of 1 month,3 months,6 months BCVA and CMT after treatment were observed.Results After the initial 3 injections of conbercept,the BCVA of the two groups was higher than before injection,and the CMT was lower than before injection,and the difference was statistically significant(P<0.05).The BCVA of the patients in the conbercept monotherapy group at 1 month,3 months,6 months after treatment was higher than that in the combination therapy group,but the difference was not statistically significant(P>0.05).CMT at one month after treatment was slightly lower than that in the combination therapy group(P>0.05),CMT and 3 months,6 months after treatment in the conbercept monotherapy group was lower than that in the combination therapy group(P<0.05).During the observation period,the vitreous injection was 7 times in the combination therapy group and 37 times in the conbercept monotherapy group.Conclusions Continuous intrav
作者
李巧
王凡
杨宁
陈基黎
刘媛媛
李明新
郭建新
LI Qiao;WANG Fan;YANG Ning;CHEN Jili;LIU Yuanyuan;LI Mingxin;GUO Jianxin(Department of Ophthalmology,Xuzhou Medical University Hospital,Xuzhou 221000,China)
出处
《中国眼耳鼻喉科杂志》
2021年第5期341-344,349,共5页
Chinese Journal of Ophthalmology and Otorhinolaryngology
关键词
视网膜中央静脉阻塞
黄斑水肿
康柏西普
黄斑格栅光凝
Central retinal vein occlusion
Macular edema
Conbercept
Macular grid photocoagulation
